Publications by authors named "Hans-Jurgen Laws"

Background: The current German guidance from 2016 recommends a Time to Antibiotics (TTA) of<60 min in children and adolescents with febrile neutropenia (FN).

Methods: Critical analysis of available studies and recent meta-analyses, and discussion of the practical consequences in the FN working group of the German Societies for Paediatric Oncology and Haematology and Paediatric Infectious Diseases.

Results: The available evidence does not support a clinically significant outcome benefit of a TTA<60 min in all paediatric patients with FN.

View Article and Find Full Text PDF

Background: Due to the high risk of severe infection among pediatric hematology and oncology patients, antimicrobial use is particularly high. With our study, we quantitatively and qualitatively evaluated, based on institutional standards and national guidelines, antimicrobial usage by employing a point-prevalence survey with a multi-step, expert panel approach. We analyzed reasons for inappropriate antimicrobial usage.

View Article and Find Full Text PDF

Background: Because infections are a major driver of morbidity and mortality in children with hematologic or oncologic diseases, antimicrobials are frequently prescribed in pediatric oncology practice. However, excess or inappropriate use of antimicrobials is directly linked to the emergence of antimicrobial resistance. Although point-prevalence studies have examined the extent of antimicrobial use, a comprehensive qualitative evaluation of individual antimicrobial prescriptions remains lacking.

View Article and Find Full Text PDF

Objective: To analyze the composition of the oral microbiome in children and adolescents with chronic nonbacterial osteomyelitis (CNO) with respect to age distribution, gender differences, effects of medication, disease activity and the influence of body site.

Methods: The oral microbiome of 20 patients (12 male and 8 female; median age 10.3 years) and 36 controls were examined.

View Article and Find Full Text PDF

Immunocompromised children and adolescents receiving treatment for cancer have an increased risk for potentially life-threatening infectious complications such as blood stream infections with Gram-positive and Gram-negative pathogens. Therefore, several centers for Pediatric Hematology and Oncology administer antibacterial prophylaxis to these patients to lower morbidity and mortality. Two pediatric specific guidelines on antibacterial prophylaxis were recently published.

View Article and Find Full Text PDF
Article Synopsis
  • A multicenter survey conducted in 36 pediatric oncology centers in Germany revealed a decline in home schooling satisfaction from 79% to 38% during the COVID-19 pandemic.
  • The main concerns for patients attending school included the risk of SARS-CoV-2 infection and potential transmission to others.
  • Many pediatric oncology centers emphasized the importance of regular social participation after intensive therapy, highlighting that ongoing restrictions have significant negative impacts on the psychosocial well-being of patients and their families.
View Article and Find Full Text PDF

Anogenital and oropharyngeal infections with human papilloma viruses (HPV) are common. Clinically manifest disease may significantly impact quality of life; the treatment of HPV-associated lesions is associated with a high rate of recurrence and invasive neoplasms, such as cervical, anal, vulvar, penile, and oropharyngeal cancers, which are characterized by significant morbidity and mortality. Vaccination against HPV is an effective and safe measure for the primary prevention of HPV-associated lesions, but immunization rates are still low in Germany.

View Article and Find Full Text PDF

Background: Familial multiple coagulation factor deficiencies (FMCFDs) are a group of inherited hemostatic disorders with the simultaneous reduction of plasma activity of at least two coagulation factors. As consequence, the type and severity of symptoms and the management of bleeding/thrombotic episodes vary among patients. The aim of this study was to identify the underlying genetic defect in patients with FMCFDs.

View Article and Find Full Text PDF

Purpose: Investigation of the current practice of diagnostics and treatment in pediatric cancer patients with febrile neutropenia.

Methods: On behalf of the German Society for Pediatric Oncology and Hematology and the German Society for Pediatric Infectious Diseases, an Internet-based survey was conducted in 2016 concerning the management of febrile neutropenia in pediatric oncology centers (POC). This survey accompanied the release of the corresponding German guideline to document current practice before its implementation in clinical practice.

View Article and Find Full Text PDF

Using retrospectively collected data from 383 infants born to HIV-1-infected mothers receiving antiretroviral therapy, we compared transmission rates and hematologic toxicity between infants receiving 2-week (short course) versus longer duration zidovudine postexposure prophylaxis. Short course resulted in lower hematologic toxicity without evidence of increased vertical transmission risk.

View Article and Find Full Text PDF

Background: Due to the potential loss of protective antibody titers after autologous hematopoietic stem cell transplantation (HSCT), revaccination is important. The aim of the study was to evaluate the current strategies in Germany, Austria and Switzerland for revaccination of children after autologous HSCT.

Methods: An internet-based survey was performed, and results were analyzed in a descriptive way.

View Article and Find Full Text PDF

Immunocompromised children and adolescents receiving treatment for cancer have a considerably increased risk for infection. Neutropenia is the most important single risk factor for infectious complications, and fever in neutropenia is considered as an emergency. Whereas guidelines for the management of fever in neutropenic adults have been established for decades, specific pediatric guidelines have not been developed until recently.

View Article and Find Full Text PDF

Background: Mycobacterium tuberculosis (M. tuberculosis) disease is a generally well-known problem among immunocompromised adults and children. In pediatric oncology, only few cases of M.

View Article and Find Full Text PDF

Objectives: Data on drug-resistant mutations (DRMs) in HIV-1-infected therapy-naïve children are scarce. The aim of this study was to determine the HIV-1 subtype distribution and the prevalence of DRMs in therapy-naïve HIV-1-infected children who received routine care at the University Hospital Düsseldorf, Düsseldorf, Germany.

Methods: Records of all HIV-1-infected children who received routine care between January 2005 and December 2015 were analyzed retrospectively.

View Article and Find Full Text PDF

Pediatric patients receiving conventional chemotherapy for malignant disease face an increased risk of bloodstream infection (BSI). Since BSI may represent an acute life-threatening event in patients with profound immunosuppression, and show further negative impact on quality of life and anticancer treatment, the prevention of BSI is of paramount importance to improve and guarantee patients' safety during intensive treatment. The great majority of all pediatric cancer patients (about 85%) have a long-term central venous access catheter in use (type Broviac or Port; CVAD).

View Article and Find Full Text PDF
Article Synopsis
  • Leishmaniasis is a disease caused by the Leishmania protozoa, commonly found in regions like South-Western Asia and the Mediterranean, and is transmitted by sandfly bites.
  • The report discusses two children with symptoms like pancytopenia and organomegaly who were initially misdiagnosed with viral infections before Leishmania was finally detected.
  • It highlights the importance of considering visceral leishmaniasis in children with similar symptoms, especially if they have traveled to endemic areas, as it can resemble other common diseases.
View Article and Find Full Text PDF

Autoimmune lymphoproliferative syndrome is frequently caused by mutations in genes involved in the Fas death receptor pathway, but for 20-30% of patients the genetic defect is unknown. We observed that treatment of healthy T cells with interleukin-12 induces upregulation of Fas ligand and Fas ligand-dependent apoptosis. Consistently, interleukin-12 could not induce apoptosis in Fas ligand-deficient T cells from patients with autoimmune lymphoproliferative syndrome.

View Article and Find Full Text PDF